Health Care • Biotechnology: Pharmaceutical Preparations
$21.94 ▲ +0.46
(+2.14%)
MKT CAP: $1.56B • VOL: 929.5K
52W L $21 52W H $95
ROARABLE / RQD
D- • 42/100
PIOTROSKI
1 / 9
GPCR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$176.6M | -$158.2M | -$102.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$141.2M | -$122.5M | -$89.6M |
| EBITDA (Normalized) | -$173.7M | -$157.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$222.2M | -$116.6M | -$79.5M |
| Capital Expenditures (CapEx) | $3.6M | $1.3M | — |
| Free Cash Flow (FCF) | -$225.8M | -$117.9M | -$79.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -19.5% | -18.0% | — |
| Cash & Short-Term Equivalents | $799.6M | $169.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.52B | $864.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GPCR.